Discovering Novel Retinal Vascular Models to Translate Neovascularization Targets Beyond Anti-VEGF into the Clinic

March 19 - 21, 2024 | Boston, MA

Accelerating Novel Retinal Vascular Target R&D into the Clinic

The 4ᵗʰ Wet AMD & Diabetic Eye Disease Drug Development Summit is returning to Boston this March to unite 70+ industry-based retinal vascular experts from the likes of Bayer, Boehringer Ingelheim, Genentech, Novartis and OcuTerra, at the only industry-dedicated forum to transform the potential of treatment of chronic, sight-threatening retinal vascular diseases to improve patient outcomes.     

18+ World-Class Pharma & Biotech Expert Speakers Include:

Past Companies in Attendance Included:

previously attending companies

Proud to Partner With:


“Great content from the most relevant players and very nice speakers from clinician and industry sides. Worth the time” 

Senior Leader, Clinical Program, Ophthalmology, Clinical Development & Medical Affairs, Boehringer Ingelheim


Other Events in the Ophthalmology & Sensory Series:


Download the Full Event Guide for More Information On:

  • Expert Speaker Faculty
  • Full Access to the 3-day Conference Agenda
  • Audience Breakdown
  • & more